Company overview
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing CATX with another company.
| Daily close (USD) | $2.71 |
| Market capitalization (USD) | $309,351,006.73 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.96 |
No matching rows. Clear the filter to see all records.
Read CATX's valuation metrics
Company size
Perspective Therapeutics, Inc.'s recorded market capitalization is $309,351,006.73. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CATX's recorded price-to-book ratio is 0.96. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Perspective Therapeutics, Inc. with Aurora
Use the snapshot above to ask a specific question about CATX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CATX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.